Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nivoxia-PG
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nivoxia-PG is a fixed-dose combination oral medication developed and marketed by Vin Medicament Pvt Ltd for the management of pain and inflammation, particularly in conditions with a neuropathic component. It contains etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor that provides potent anti-inflammatory and analgesic effects by reducing prostaglandin synthesis, and pregabalin, an alpha-2-delta ligand that modulates voltage-gated calcium channels to decrease the release of excitatory neurotransmitters. Formulated as a sustained-release (SR) tablet, Nivoxia-PG is designed to provide prolonged therapeutic relief, making it suitable for chronic pain management in conditions such as osteoarthritis, rheumatoid arthritis, and various neuropathic pain syndromes.
- Brand names
- Nivoxia-PGNivoxia-PG Tablet SR
- Other names
- etoricoxib + pregabalin
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Nivoxia-PG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nivoxia-PG.